Edgewise Therapeutics, Inc.
EWTX
$29.69
-$0.81-2.66%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -26.61% | -19.15% | -14.66% | -43.03% | -31.58% |
| Total Depreciation and Amortization | -8.59% | -5.32% | 6.18% | 5.52% | 18.01% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 63.43% | 65.63% | 230.94% | 314.64% | 72.26% |
| Change in Net Operating Assets | -61.72% | -128.21% | -180.30% | -105.17% | 3,553.23% |
| Cash from Operations | -43.16% | -27.04% | -24.84% | -32.41% | -0.47% |
| Capital Expenditure | 73.36% | 82.88% | 77.38% | 85.19% | -70.19% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 135.12% | 38.34% | -531.29% | 116.40% | -21.91% |
| Cash from Investing | 137.85% | 40.82% | -533.97% | 116.36% | -22.46% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 37.31% | -53.23% | 9,309.65% | -99.06% | -94.53% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 179.17% | -- | -100.00% |
| Cash from Financing | 37.31% | -50.23% | 9,542.98% | -99.08% | -94.54% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 582.32% | 96.74% | -149.29% | 114.79% | -105.91% |